Literature DB >> 25175600

Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation.

Xuan Gao1, Junyan A Ji, Karthik Veeravalli, Y John Wang, Taylor Zhang, William Mcgreevy, Kai Zheng, Robert F Kelley, Michael W Laird, Jun Liu, Mary Cromwell.   

Abstract

The long serum half-lives of mAbs are conferred by pH-dependent binding of IgG-Fc to the neonatal Fc receptor (FcRn). The Fc region of human IgG1 has three conserved methionine residues, Met252, Met358, and Met428. Recent studies showed oxidation of these Met residues impairs FcRn binding and consequently affects pharmacokinetics of therapeutic antibodies. However, the quantitative effect of individual Met oxidation on Fc-FcRn binding has not been addressed. This information is valuable for defining critical quality attributes. In the present study, two sets of homodimeric site-directed IgG1 mutations were generated to understand how individual Fc Met oxidation affects FcRn binding. The first approach used Met to Leu mutants to block site-specific Met oxidation. In the other approach, Met to Gln mutants were designed to mimic site-specific Met oxidation. Both mutagenesis approaches show that either Met252 or Met428 oxidation alone significantly impairs Fc-FcRn binding. Met252 oxidation has a more deleterious effect on FcRn binding than M428 oxidation, whereas Met428 oxidation has a bigger destabilization effect on the thermal stability. Our results also show that Met358 oxidation does not affect FcRn binding. In addition, our study suggests that Met to Gln mutation may serve as an important tool to understand Met oxidation.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  HPLC; calorimetry; critical quality attributes; monoclonal antibody; neonatal Fc receptor; oxidation; protein binding; serum half-life; stability; surface plasmon resonance

Mesh:

Substances:

Year:  2014        PMID: 25175600     DOI: 10.1002/jps.24136

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  25 in total

1.  Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies.

Authors:  Rong Yang; Tushar Jain; Heather Lynaugh; R Paul Nobrega; Xiaojun Lu; Todd Boland; Irina Burnina; Tingwan Sun; Isabelle Caffry; Michael Brown; Xiaoyong Zhi; Asparouh Lilov; Yingda Xu
Journal:  MAbs       Date:  2017-02-14       Impact factor: 5.857

2.  Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.

Authors:  Yanli Zhuang; Di Chen; Amarnath Sharma; Zhenhua Xu
Journal:  AAPS J       Date:  2018-10-15       Impact factor: 4.009

3.  Comprehensive Characterization of Relationship Between Higher-Order Structure and FcRn Binding Affinity of Stress-Exposed Monoclonal Antibodies.

Authors:  Daisuke Tsuchida; Katsuyoshi Yamazaki; Satoko Akashi
Journal:  Pharm Res       Date:  2015-12-22       Impact factor: 4.200

4.  Comparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc Glycoforms.

Authors:  Olivier Mozziconacci; Solomon Okbazghi; Apurva S More; David B Volkin; Thomas Tolbert; Christian Schöneich
Journal:  J Pharm Sci       Date:  2016-01-11       Impact factor: 3.534

Review 5.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

6.  Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation.

Authors:  Susanna K Elledge; Hai L Tran; Alec H Christian; Veronica Steri; Byron Hann; F Dean Toste; Christopher J Chang; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

Review 7.  Effects of localized interactions and surface properties on stability of protein-based therapeutics.

Authors:  Brittney J Mills; Jennifer S Laurence Chadwick
Journal:  J Pharm Pharmacol       Date:  2016-11-10       Impact factor: 3.765

8.  Toward an era of utilizing methionine overproducing hosts for recombinant protein production in Escherichia coli.

Authors:  Karthik Veeravalli; Michael W Laird
Journal:  Bioengineered       Date:  2015-03-24       Impact factor: 3.269

Review 9.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

10.  Mitigation of Oxidation in Therapeutic Antibody Formulations: a Biochemical Efficacy and Safety Evaluation of N-Acetyl-Tryptophan and L-Methionine.

Authors:  Michelle Z Dion; Danielle Leiske; Vikas K Sharma; Christina L Zuch de Zafra; Cleo M Salisbury
Journal:  Pharm Res       Date:  2018-10-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.